The Switzerland-based company, founded in 2014, offers healthcare biomaterials that optimize the interface between implantable medical devices and biological tissues. Hylomorph's bio-engineered implants prevent postoperative complications, such as fibrosis, infection, and migration, by using advanced methods that combine biotech and surface micro-engineering. The company's first indication for use is in cardiac pacemakers and defibrillators, and neurostimulators, which improves the quality of life for patients and the quality of care by healthcare professionals. Hylomorph has recently completed its Series B funding round.